Key facts
- Austral Dx’s last known valuation is $5.4M (Jun 2025).
- It has raised $5.3M; the latest was Early Stage VC ($2.9M) in Jun 2025.
- Notable investors include Kima Ventures, Agoranov, Super Capital, Better Angle, Aloe Private Equity — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Austral Dx
- ·The full record, as it builds
Funding rounds
No funding rounds for Austral Dx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Austral Dx
Developer of a diagnostic device designed for the screening, diagnosis, and monitoring of cardiac and pulmonary conditions. The company's device utilizes non-invasive ultrasound analysis to quickly evaluate patients presenting with symptoms such as dyspnea or chest pain, providing healthcare professionals with diagnostic information that improves care prioritization, minimizes unnecessary imaging, and improves triage and treatment efficiency.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2021
- Employees
- 9
- Website
- australdx.fr/
- Ownership
- Privately Held (backing)
Austral Dx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Austral Dx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Austral Dx in its N-PORT filings yet. We sweep new filings monthly.